Proteomic Based Drug Discovery Summit 2025

Start: Tuesday, February 11, 2025 8:30AM
End: Thursday, February 13, 2025 4:30PM

Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year, Sanofi has dedicated $700M to Belharra Therapeutics to develop a proteomics platform and Galapagos has partnered with Bridgene Bio to combine chemoproteomics with computational tools.

This is the time to harness the power of proteomics to accelerate your drug development process and de-risk your pipeline.

The Inaugural Proteomics-Based Drug Discovery Summit comes to Boston as the first industry dedicated event to help solve bottlenecks across your drug development chain including hit screening, target validation, hit to lead progression and in vivo translation to leverage the power of the proteome and drug the "undruggable".

In 2025, make sure you join experts where you will hear exclusive data revealed, towards supercharging your experiments for screening compound libraries, unravelling the mechanism of action, deconvoluting protein-protein interactions and determining drug potency to gear your proteomics platforms for faster development of more effective drugs to change patient lives.

URLs:
Tickets: https://go.evvnt.com/2674449-2?pid=3698
Brochure: https://go.evvnt.com/2674449-3?pid=3698

Prices:
Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4197.00,
Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3597.00,
Service Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 5097.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3598.00,
Academic Pricing - Conference + 1 Workshop: USD 3098.00,
Service Provider Pricing - Conference + 1 Workshop: USD 4398.00,
Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,
Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,
Service Provider Pricing - 2 Day Pass (Conference Only): USD 3699.00

Speakers: Alex Campos, Senior Director - Systems Biology and Proteomics, Plexium Inc., Bekim Bajrami, Associate Scientific Director, Biogen, Chia-Feng Tsai, Senior Scientist, Scorpion Therapeutics, Chris Adams, Director - Proteomics, Rezo Therapeutics, Debora Bonenfant, Vice President, Head of Proteomics, Monte Rosa Therapeutics, Fiona Pachl, Associate Principal Scientist - Chemical Biology and Proteomics, AstraZeneca, Francisco Garcia, Principal Scientist, Novartis AG, Hai-Tsang (Hubert) Huang, Research Scientist, Cancer Program, The Broad Institute of MIT and Harvard, Jagat Adhikari, Associate Director - Translational Proteomics, Covant Therapeutics, Katherine Donovan, Director - Managing and Lead Scientist, Dana-Farber Cancer Institute, Mahmud Hossain, Senior Scientist - Disease Profiling and Functional Genomics, Proteomics, Sanofi, Michelle Dubuke, Principal Scientist - Chemoproteomics, HYKU Biosciences, Ning Deng, Director - IMTAC Discovery, BridGene Biosciences Inc., Praveen Kumar, Senior Bioinformatician - Proteomics, AstraZeneca, Rhushikesh Kulkarni, Principal Scientist, Pfizer, Thao Nguyen, Proteomics Scientist, Calico Life Sciences LLC, Tyler Bechtel, Chemical Biology and Proteomics Scientist, Bayer, Tyzoon Nomanbhoy, Vice President, Chemical Biology, Vicinitas Therapeutics, Yan Sun, Scientist II, Relay Therapeutics